Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D known ✓ | O15399 | 1/20 | 0.32 |
| ▸ | GRIN3B known ✓ | O60391 | 1/20 | 0.32 |
| ▸ | GRIN1 known ✓ | Q05586 | 1/20 | 0.32 |
| ▸ | GRIN2A known ✓ | Q12879 | 1/20 | 0.32 |
| ▸ | GRIN2B known ✓ | Q13224 | 1/20 | 0.32 |
| ▸ | GRIN2C known ✓ | Q14957 | 1/20 | 0.32 |
| ▸ | GRIN3A known ✓ | Q8TCU5 | 1/20 | 0.32 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | LDHA | P00338 | 1/20 | 0.35 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.35 |
| ▸ | CTH | P32929 | 1/20 | 0.32 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29059552 | 1.00 | RAB9A (0.36) | RAB9AHTTLDHASRRGRIN2D | |
| Hydrochloric Acid SCHEMBL8085461 | 0.97 | HTT (0.35) | RAB9AHTTLDHASRRGRIN2D | |
| SCHEMBL42019 | 0.97 | LDHA (0.37) | RAB9AHTTLDHASRRCTH | |
| SCHEMBL412337 | 0.97 | LDHA (0.37) | RAB9AHTTLDHASRRCTH | |
| Ammonia Solution, Strong SCHEMBL23014704 | 0.94 | LDHA (0.35) | RAB9AHTTLDHASRRCTH | |
| SCHEMBL31553566 | 0.94 | LDHA (0.35) | RAB9AHTTLDHASRRCTH | |
| SCHEMBL6130079 | 0.94 | LDHA (0.35) | RAB9AHTTLDHASRRCTH | |
| SCHEMBL29973268 | 0.94 | LDHA (0.35) | RAB9AHTTLDHASRRCTH | |
| SCHEMBL10490033 | 0.94 | LDHA (0.35) | RAB9AHTTLDHASRRCTH | |
| SCHEMBL3911509 | 0.94 | LDHA (0.35) | RAB9AHTTLDHASRRCTH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116601173-A | Anti-ceruloplasmin antibodies and uses thereof | 阿雷克森制药公司 | 2023-08-15 | — | — | CN | claimed |
| US-11685940-B2 | Method of replicating or amplifying circular DNA | MODERNA ENZYMATICS CO., LTD. (JP) | 2023-06-27 | — | — | US | claimed |
| CN-116283606-A | Method and device for continuously synthesizing tricine hydrochloride and intermediate thereof | 博瑞生物医药泰兴市有限公司 | 2023-06-23 | — | — | CN | claimed |
| US-10844369-B2 | Isolation of cell-free nucleic acids from bodily fluid samples using solid chaotropic agents | QUAN NANCY (US) | 2020-11-24 | — | — | US | claimed |
| US-20200199574-A1 | ISOLATION OF CELL-FREE NUCLEIC ACIDS FROM BODILY FLUID SAMPLES USING SOLID CHAOTROPIC AGENTS | QUAN NANCY (US) | 2020-06-25 | — | — | US | claimed |
| EP-4748944-A1 | METHOD FOR PRODUCING CIRCULAR DNA | Moderna Enzymatics Co., Ltd. (JP) | 2026-05-27 | — | — | EP | disclosed |
| US-12392780-B2 | Support for fluorescence polarization immunoassay, fluorescence polarization immunoassay kit and fluorescence polarization immunoassay | Tianma Japan, Ltd. (JP) | 2025-08-19 | — | — | US | disclosed |
| US-20250236900-A1 | Method for Producing Double-Stranded DNA Molecules Having Reduced Sequence Errors | MODERNA ENZYMATICS CO LTD (JP) | 2025-07-24 | — | — | US | disclosed |
| WO-2025102074-A1 | DEVICES AND SYSTEMS FOR THE DETECTION OF ANALYTES AND METHODS OF USING THE SAME | BAEBIES, INC. (US) | 2025-05-15 | — | — | WO | disclosed |
| EP-4553500-A1 | METHOD FOR DETECTING AND DETERMINING THE BINDING STRENGTH OF AT LEAST ONE ANALYTE IN A SAMPLE | Attomol GmbH Molekulare Diagnostika (DE) | 2025-05-14 | — | — | EP | disclosed |
| CN-119932113-A | Suspension system for adeno-associated virus production | 生命技术公司 | 2025-05-06 | — | — | CN | disclosed |
| CN-119792251-A | Application of nordihydroguaiaretic acid as mycobacterium tuberculosis malic acid synthase lead inhibitor | 重庆医科大学国际体外诊断研究院 | 2025-04-11 | — | — | CN | disclosed |
| US-20050239100-A1 | Method for amplifying nucleic acid sequence | TAKARA BIO INC. (JP) | 2005-10-27 | — | — | US | disclosed |
| US-6951722-B2 | Method for amplifying nucleic acid sequence | TAKARA BIO INC. (JP) | 2005-10-04 | — | — | US | disclosed |
| US-20050123950-A1 | Method for amplifying nucleic acid sequence | TAKARA BIO NIC. (JP) | 2005-06-09 | — | — | US | disclosed |
| US-20030073081-A1 | Method for amplifying nucleic acid sequence | TAKARA SHUZO CO., LTD (JP) | 2003-04-17 | — | — | US | disclosed |
| CN-1350581-A | Method for amplifying nucleic acid sequences | TAKARA SHUZO CO (JP) | 2002-05-22 | — | — | CN | disclosed |
| EP-1167524-A1 | METHOD FOR AMPLIFYING NUCLEIC ACID SEQUENCE | Takara Shuzo Co, Ltd. (JP) | 2002-01-02 | — | — | EP | disclosed |
| US-4835101-A | Luminescent analyses with enhanced storage stability | KALLESTAD DIAGNOSTICS, INC. (US) | 1989-05-30 | — | — | US | disclosed |
| EP-0235970-A1 | Luminescent analyses with enhanced storage stability | ERBAMONT, INC. (US) | 1987-09-09 | — | — | EP | disclosed |